OPALE, the Organization
for Partnerships in Leukemia
The OPALE Carnot institute is a healthcare industry’s preferred partner for the research and development of innovative solutions aimed at diagnosis, treatment and follow-up of patients in the field of leukemia and related diseases, the deadliest blood cancer and first child cancer.
Unique leukemia R&D partnering opportunities
The OPALE Carnot Institute gives healthcare companies unique access to the expertise of an internationally unparalleled consortium in the field of leukemia and related diseases. Our aim is to prolong or save the lives of more patients by accelerating therapeutic and diagnostic innovation across the entire research and development value chain.
Explore our offer
Carnot, a label of excellence
Granted by the French Ministry of Higher Education, Research and Innovation, the Carnot label is prestigious and highly selective.
Being labelled Carnot is a guarantee of scientific and operational excellence in R&D collaborations for our industrial partners.
The Carnot institutes follow their namesake Charter to guarantee top-tier collaborative research, effectively driving industrial advancements while ensuring ongoing scientific revitalization within the Carnot community.
"The OPALE Carnot Institute addresses many of the needs of manufacturers in the leukemia market, thanks to the specialization and depth of its R&D offering, accessible through a one-stop shop."
Medical Director of a pharmaceutical company
Member of OPALE's Strategic Advisory Committee
"Accelerating the emergence of innovative solutions for the diagnosis, treatment, and follow-up of patients in the field of leukemia and related diseases"
Pr Hervé Dombret
OPALE's Chairman
News
Nicolas Duployez lauréat du Prix de l’Institut de la Leucémie
24/09/2026
Nicolas Duployez, membre de CANTHER au sein d’OPALE, est le premier lauréat du Prix de l’Institut de la Leucémie pour ses travaux en génomique.
> Read moreMTI en leucémie : construire une preuve préclinique robuste
17/09/2026
Pour un MTI, la preuve préclinique ne se limite pas à montrer une efficacité. OPALE décrypte les preuves nécessaires avant le passage vers le clinique.
> Read moreKevin Carvalho rejoint l’Institut Carnot OPALE
10/09/2026
Kevin Carvalho rejoint OPALE comme Responsable Développement et Innovation pour développer partenariats, offres et nouveaux modèles de valorisation en leucémies.
> Read more